Journal
CURRENT DRUG TARGETS
Volume 16, Issue 3, Pages 219-225Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1389450116666150113122229
Keywords
Anti-platelet agents; inflammatory bowel diseases; platelets; thrombosis
Categories
Funding
- National Science Foundation of China [81270477, 81170345]
- Shanghai Tenth People's Hospital Project for cultivating tutor of doctor [12HBBD110]
- bilateral cooperation between Poland and China
- Plus program of the Polish Ministry of Science and Higher Education [IP2012 010772]
Ask authors/readers for more resources
Platelets play a crucial role in immune responses. Impaired platelet activation may cause persistent mucosal inflammation through P-selectin, CD40-CD40L and other systems influencing granulocytes, macrophages or endothelial cells. Pharmacological regulation of platelet activation may reduce thromboembolism and limit the interaction of platelets with endothelial and inflammatory cells, in turn weakening the inflammatory responses. In this review we focus on pathophysiological activities of platelets in inflammatory bowel diseases and discuss the studies on currently available anti-platelet therapies in the treatment of gastrointestinal inflammation. Finally, we provide a prospective view to new anti-platelet agents currently under development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available